In vivo pO2 imaging in the porcine model with perfluorocarbon F-19 NMR at low field

Magnetic Resonance Imaging

Volumn 14, Issue 1, 1996, Pages 103-114

  Thomas, Stephen R ^a   Pratt, Ronald G ^a   Millard, Ronald W ^a   Samaratunga, Ranasinghage C ^a   Shiferaw, Yoseph ^a   McGoron, Anthony J ^a   Tan, Kim Kiat ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

F 19 NMR; Fluorine 19 magnetic resonance imaging (MRI); Liver; Lung; Oxygen imaging; Perfluorocarbon F 19 NMR; pO2 imaging; Spleen

Indexed keywords

FLUOROCARBON; PERFLUOROTRIBUTYLAMINE; POLOXAMER; BLOOD SUBSTITUTE; OXYGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL OXYGEN TENSION; ARTICLE; CALIBRATION; DRUG TISSUE LEVEL; EMULSION; FEMALE; IMAGE ANALYSIS; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER; LUNG; LUNG ALVEOLUS OXYGEN TENSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXYGEN TENSION; PHARMACEUTICS; PRIORITY JOURNAL; SIGNAL NOISE RATIO; SPLEEN; SWINE; VENOUS OXYGEN TENSION; ANIMAL; BLOOD; BREATHING; CHEMISTRY; METHODOLOGY;

ANIMALIA; SUIDAE; SUS SCROFA;

ANIMALS; BLOOD SUBSTITUTES; FEMALE; FLUOROCARBONS; LIVER; LUNG; MAGNETIC RESONANCE SPECTROSCOPY; OXYGEN; RESPIRATION; SPLEEN; SWINE;

EID: 0029665210     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0730-725X(95)02046-V     Document Type: Article

References (37)

1. Alpha Therapeutic Corporation, 5555 Valley Blvd., Los Angeles, CA 92121 (Distributor) and Green Cross Corporation, Osaka, 932-1201 1/3, Camon-Cho, Joto-ku, Japan (Manufacturer). (Products: Fluosol-DA and Oxypherol-ET.)
2. Alliance Pharmaceutical Corp., 3040 Science Park Road, San Diego, CA 92121. (Product: Oxygent-HT.)
3. HemaGen/PFC. 11810 Borman Drive, St. Louis, MO 63146.
4. Kaufman, R.J. Perfluorochemical emulsions as blood substitutes. In: J. Sjoblom (Ed). Emulsions - A Fundamental and Practical Approach. The Netherlands: Kluwer Academic Publishers; 1992: pp. 207-226.
5. Riess, J.G. The design and development of improved fluorocarbon-based products for use in medicine and biology. Art. Cells Blood Subs Immob. Biotechnol. 22: 215-254; 1994.
6. Riess, J.G. Overview of progress in the fluorocarbon approach to in vivo oxygen delivery. Biomat. Art. Cells Immob. Biotechnol. 20(2-4): 183-202; 1992.
7. Wessler, E.P.; Iltis, R.; Clark, L.C., Jr. The solubility of oxygen in highly fluoridated liquids. J. Fluor. Chem. 9:137-146; 1977.
8. Thomas, S.R. The biomedical applications of fluorine-19 NMR. In: C.L. Partain, R.R. Price, J.A. Patton, et al. (Eds). Magnetic Resonance Imaging, Second Edition, Vol. II: Physical Principles and Instrumentation. Philadelphia: W.B. Saunders; 1988: pp. 1536-1552.
9. 19F and dissolved oxygen. In: D. Bruley, H.I. Bicher, D. Reneau (Eds). Advances in Experimental Medicine and Biology-Oxygen Transport to Tissue IV, Vol. 180. New York: Plenum Publishing Corporation; 1985: pp. 835-845.
10. Thomas, S.R.; Clark, Jr., L.C.; Ackerman, J.L.; Pratt, R.G.; Hoffmann, R.E.; Busse, L.J.; Kinsey, R.A.; Samaratunga, R.C. MR imaging of the lung using liquid perfluorocarbons. J. Comput. Assist. Tomogr. 10(1): 1-9; 1986.
11. Fishman, J.E.; Joseph, P.M.; Floyd, T.F.; et al. Oxygen-sensitive F-19 NMR imaging of the vascular system in vivo. Magn. Reson. Imaging 5:279-285; 1987.
12. Mason, R.P.; Jeffrey, F.M.H.; Malloy, C.R.; Babcock, E.E.; Antich, P.P. A noninvasive assessment of myocardial oxygen tension: 19F NMR spectroscopy of sequestered perfluorocarbon emulsion. Magn. Reson. Med. 27:310-317; 1992.
13. 19F NMR. Magn. Reson. Med. 21:233-241; 1991.
14. Wilson, C.A.; Berkowitz, B.A.; McCuen, B.W., II; Charles, H.C. Measurement of preretinal oxygen tension in vitrectomized human eye using fluorine-19 magnetic resonance spectroscopy. Arch. Ophthalmol. 110:1098-1100; 1992.
15. Mason, R.P.; Shukla, H.; Antich, P.P. In vivo oxygen tension and temperature: Simultaneous determination using 19F NMR spectroscopy of perfluorocarbon. Magn. Reson. Med. 29:296-302; 1993.
16. 19F NMR. Magn. Reson. Med. 29:446-458; 1993.
17. Parhami, P.; Fung, B.M. Fluorine-19 relaxation study of perfluoro chemicals as oxygen carriers. J. Phys. Chem. 87:1928-1931; 1983.
18. Lai, C.S.; Stair, S.J.; Miziorko, H.; Hyde, J.S. Effect of oxygen and the lipid spin label TEMPO-laurate on fluorine-19 and proton relaxation rates of the perfluorochemical blood substitute, FC-43 emulsion. J. Magn. Reson. 57:447-452; 1984.
19. 1 of perfluorocarbon blood substitute emulsions. J. Magn. Reson. Imaging 4:631-635; 1994.
20. 2 imaging in vivo with perfluorocarbon F-19 NMR: Tracking oxygen from the airway through the blood to organ tissues. Art. Cells Blood Subs. Immob. Biotechnol. 22(4): 1029-1042; 1994.
21. The Green Cross Corporation. Potential uses of perfluorochemical artificial blood for experimental studies in physiology, biology, biochemistry, chemotherapy, toxicology, metabolism, etc. FC-43 emulsion. Technical Information Series No. 3, September 4, 1976.
22. Yokoyama, K.; Suzuki, A.; Utsumi, I.; Naito, R. Determination of particle size distribution of fluorocarbon emulsion by means of centrifugal sedimentation. Chem. Pharm. Bull. (Tokyo) 22:2966-2971; 1974.
23. 19F nuclear magnetic resonance imaging of perfluorocarbon compounds. Med. Phys. 13(4): 518-524; 1986.
24. 19F MR imaging. J. Comput. Assist. Tomogr. 12(5): 824-835; 1988.
25. Thomas, S.R.; Ackerman, J.L.; Kereiakes, J.G. Practical aspects involved in the design and set up of a 0.15T, 6-coil resistive magnet, whole body NMR imaging facility. Magn. Reson. Imaging 2:341-348; 1984.
26. Samaratunga, R.C.; Busse, L.J.; Pratt, R.G.; Thomas, S.R. Resonator coils for magnetic resonance imaging at 6 MHz. Med. Phys. 15(2):235-240; 1988.
27. 1 MRI at low fields (0.14T). Med. Phys. 21(5):697-705; 1994.
28. Pykett, I.L.; Rosen, B.R.; Buonanno, F.S.; Brady, T.J. Measurement of spin-lattice relaxation times in nuclear magnetic resonance imaging. Phys. Med. Biol. 28:723-729; 1983.
29. 2 using perfluorocarbon (PFC) F-19 NMR. In: Book of abstracts: Eleventh Annual Meeting of the Society of Magnetic Resonance in Medicine. Berkeley, CA: SMRM; 1992: 4311.
30. 2) using F-19 in nuclear magnetic resonance (NMR) imaging. Doctoral dissertation (Ph.D. thesis, unpublished). Department of Physics, University of Cincinnati, Cincinnati, OH 45220-0011.
31. Pratt, R.G.; Thomas, S.R.; Millard, R.W.; Samaratunga, R.C.; Naseem, M.H. Quantitation of perfluorocarbon blood substitutes in tissues using F-19 magnetic resonance spectroscopy. Biomat. Art. Cells Immob. Biotechnol. 20(2-4):921-924; 1992.
32. Reiss, J.G.; Arlen, C.; Greiner, J.; Le Blanc, M.; Manfredi, A.; Pace, C.; Varescon, C.; Zarif, L. Design, synthesis and evaluation of fluorocarbons and surfactants for in vivo applications: New perfluoroalkylated polyhydroxylated surfactants. In: R.M.S. Chang, R.P. Geyer (Eds). Blood Substitutes. New York: Marcel Dek-ker, Inc.; 1989: pp. 421-430.
33. Comroe, J.M., Jr. Alveolar ventilation. In: Physiology of Respiration, 2nd ed. Chicago: Yearbook Medical Publishers, Inc.; 1974: pp. 8-21.
34. Glenny, R. W. Spatial correlation of regional pulmonary perfusion. J. Appl. Physiol. 72(6):2378-2386; 1992.
35. Nanney, L.; Fink, L.M. and Virmani, R. Perfluorochemicals: Morphologic changes in infused liver, spleen, lung, and kidney of rabbits. Arch. Pathol. Lab. Med. 108: 631-637; 1984.
36. 2-supply of the liver. In: D.W. Lübbers, et al. (Eds). Oxygen Transport in Blood and Tissue. Stuttgart: George Thiem Verlag; 1968: pp. 242-251.
37. Vaupel, P.; Frinak, S.; Müller-Klieser, W.; Manz, R. The end of a postulate: There are no hostile metabolic conditions within the normal spleen. Biblthca. Anat., No. 209:403-406 (Karger, Basel); 1981.